Re: Farmas USA
SNTA
Artículo SA:
Here's Why I'm Betting On Synta Pharmaceuticals
The company is approaching the first interim analysis of its Phase 3 GALAXY-2 trial of ganetespib in second-line non-small-cell lung carcinoma, which, if positive, should unlock considerable shareholder value.